Background-Non-Hispanic Blacks (Blacks) and Hispanics have a lower likelihood of being eligible for medication therapy management (MTM) services than do non-Hispanic Whites (Whites) based on Medicare MTM eligibility criteria.
INTRODUCTION
The importance of documenting racial and ethnic disparities and exploring solutions for these disparities has been widely and keenly recognized by policy makers and researchers. 1, 2 The nation has attempted to address racial and ethnic disparities in recent history. In the 1985 Report of the Secretary's Task Force on Black and Minority Health, the first comprehensive government report accounting for racial and ethnic disparities in health in the United States, policy makers rightly noted the "national paradox of phenomenal scientific achievement and steady improvement in overall health status" and coexisting "persistent, significant health inequalities [that] exist for minority Americans". 1, 2 A new action plan to reduce racial and ethnic disparities recently released by the Department of Health and Human Services (HHS) was touted as the "most comprehensive federal commitment yet to reducing racial and ethnic health disparities". 2 A major goal of this action plan was to increase the accountability of HHS for demonstrating progress in reducing disparities, specifically capitalizing on the provisions in the Affordable Care Act of 2010 that benefit diverse communities. 2 Accompanied by the efforts by researchers and the U.S. government to reduce racial and ethnic health disparities is a discomforting pattern that has aroused growing concern: as reported by the Agency for Healthcare Research &Quality, 3 racial and ethnic minorities still lag behind majority non-Hispanic Whites (Whites) on many health and health care measures. Some disparity measures even indicate worsening disparities. The academic community has also reported such a pattern of persistent disparities. [4] [5] [6] [7] Perplexed by such phenomena, the research community and policy-makers have recently explored root causes for the more resistant disparities. For instance, Weinick and Hasnain-Wynia cautioned that quality improvement efforts should be devised carefully so that disparities can be reduced. 8 Specifically, they suggested that quality improvement should not create perverse incentives lest providers avoid serving minority populations. Considering root causes of disparities from a wider perspective, Woolf and Braveman suggested that progress in narrowing health disparities can be achieved only by making modification to policies on community development, land use, housing, education, jobs, child care, and transportation. 9 Medicare is the largest regulator and purchaser of health care in the U.S. 10 Its policies are widely imitated, and it is well positioned to be a leader in reducing racial and ethnic disparities. Medicare's policy leverage was exemplified when hospitals desegregated in 1966 in order to receive Medicare reimbursement. 10 Medicare Prescription Drug & Modernization Act (MMA) established Medicare prescription drug (Part D) benefit in 2006 which can positively impact racial and ethnic minorities due to many carefully crafted measures: 11 a low-income subsidy program was established by MMA to help qualified persons pay Part D premium and cost sharing; individuals dually eligible for Medicare and Medicaid were automatically enrolled in Part D and automatically received a low-income subsidy. Because minorities are more likely to have low income and be dually eligible than do Whites, these measures benefited minorities.
Medication therapy management (MTM) services are a relatively new type of benefit for certain Medicare beneficiaries. MTM services were added to the Medicare benefits package in 2006 when the Centers for Medicare & Medicaid Services (CMS) also required prescription drug plans for Medicare beneficiaries to offer MTM services for targeted individuals according to MMA. 12 MTM services are a distinct group of services to optimize therapeutic outcomes, and the core components of MTM services are the development of a medication treatment plan and the integration of medication management plan into all health services provided to patients. 13 MTM services can improve patient therapeutic outcomes in a cost-effective manner, particularly for chronic disease management. [14] [15] [16] According to the MMA, Part D plans are required to offer MTM services to only Medicare Part D beneficiaries who meet the eligibility criteria of multiple chronic conditions, multiple covered medications, and are likely to incur annual drug costs that exceed a certain threshold. 12 The eligibility criteria for MTM services are flexible, and Part D plans can determine their own MTM eligibility thresholds within the legislative framework. 12 In regulations for Part D plans for 2010-2011, CMS stipulated that the MTM eligibility thresholds cannot be higher than eight Part D drugs, three chronic conditions, and $3,000 in drug costs. 17 The establishment of MTM services in Medicare presented a historical opportunity to reduce racial and ethnic disparities related to chronic conditions, because some chronic conditions targeted by MTM programs, e.g., diabetes and hypertension, are more prevalent among minority elderly than among their White counterparts. 18 However, Wang and colleagues recently found in analyses of historical data before Part D implementation, racial and ethnic minorities would be less likely than Whites to be eligible for MTM services. 19 These findings should be expected because Medicare MTM eligibility criteria are predominantly utilization-based, and racial and ethnic minorities typically use fewer prescription medications and incur lower costs on prescription drugs than do Whites within the Medicare population. 20, 21 This study aimed to examine the historical trend of disparity implications of Medicare MTM eligibility criteria from 1996-1997 to [2007] [2008] . The main goal of this analysis was to inform decision-makers whether or not the disparity implications of MTM eligibility criteria may decrease over time without modifying the MTM eligibility criteria.
METHODS

Data Source
This was a cross-sectional analysis of Medicare beneficiaries in a secondary database, Medical Expenditure Panel Survey (MEPS; 1996 -1997 -2008 . 22 As a large-scale national federal survey, MEPS was started in 1996 by AHRQ. MEPS collects information from a nationally representative sample of families, individuals, their medical providers, and employers. Information on individuals includes sociodemographic characteristics, health status, chronic conditions, access to care, satisfaction with care, utilization of health services and prescription medications and their costs, and sources of payment for these costs. MEPS also surveys medical providers including hospitals, physicians, home health care providers, and pharmacies identified by individual survey respondents. These sources serve a data quality improvement purpose because information from medical providers is used to supplement or replace information collected from survey respondents. MEPS uses an overlapping panel design whereby a new panel (group) of patients is added to the survey population every year, and each panel of individuals is surveyed in several rounds to cover 2 full calendar years. 22 The response rates to MEPS survey were 77.7%, 66.4%, 56.9%, and 59.3% for 1996, 1997, 2007, and 2008, respectively. 22 The response rates among Medicare populations were not reported in MEPS.
The most recent complete data were from 2008 at the time of this analysis. This study used data from 1996-1997 and 2007-2008 . Data from 2 years were combined to represent each time period to achieve adequate statistical power. Additionally, 2-year periods instead of 1-year periods were compared to address statistical issues with using MEPS data for longitudinal analysis. 22 Because of sampling variation from one year to the next in MEPS, some artificial statistically significant difference may result. The method of pooling multiple years has been suggested as one technique to address this concern. 22 Information used in this study is freely available in downloadable data files. 22 
Determining MTM Eligibility
When analyzing MTM eligibility criteria, we studied both 2008 thresholds and 2010-2011 thresholds to explore whether CMS strategies of lowering eligibility thresholds had a desirable effect of reducing or eliminating MTM disparities. This study accounted for the wide variation in eligibility thresholds by examining three representative values: the lower limit, median, and upper limit. For example, in 2008, these three values for the criterion based on the number of covered drugs were 2, 5, 15, respectively; the values for the criterion based on the number of chronic conditions were 2, 3, and 5, respectively; and the drug cost thresholds were $4,000. 23 Because individuals must meet all three MTM eligibility criteria to be eligible, there were then 3*3*1=9 different combinations of the thresholds to analyze, where the first and the second "3" represent the number of representative values for the criterion based on the number of covered drugs, and number of representative values for the criterion based on the number of chronic conditions, respectively, and the value "1" designates the only threshold on drug costs. 12 The combination for the medians (5 drugs, 3 chronic conditions) and $4,000 in drug costs were analyzed in the main analysis, and all other eight combinations were analyzed in eight sensitivity analyses. When applying the thresholds of $4,000 to 1996-1997 data, 2008 dollars were converted to dollars of the study years by using the consumer price index for medical care. Since the threshold for drug cost in 2007 was also $4,000, the cost threshold of $4000 was not converted for 2007. 17 When analyzing the MTM eligibility thresholds for 2010-2011, similar methods were used as for the methods for 2008 eligibility thresholds. For 2010-2011, the representative values for the eligibility thresholds for the criterion based on the number of D drugs were 2 (lower limit), 5 (median), and 8 (upper limit), respectively. 17 There were only two thresholds for the criterion on the number of chronic conditions: 2 and 3. The drug cost threshold was $3,000. Therefore, there were 3*2*1=6 combinations of thresholds for analysis for 2010-2011. The combination of 5 drugs, 3 chronic conditions, and $3,000 in drug costs was analyzed in the main analysis. All other combinations were analyzed in the sensitivity analyses.
When counting the number of chronic conditions in MEPS, a raw count of chronic conditions among a list of 25 chronic conditions was used. 24 This list was devised by Daniel and Malone as chronic conditions applicable to Medicare beneficiaries when they studied the characteristics of individuals meeting MTM eligibility criteria. This list has included all major chronic conditions targeted in MTM programs. 17 
Theoretical Framework
Andersen's Behavioral Model in Health Services Utilization was used as the theoretical framework for including population characteristics in the regression models because MTM eligibility criteria are predominantly based on the utilization and costs of prescription medications. 25 Therefore, patient characteristics in the model included predisposing factors (age, gender, and marital status), enabling factors (highest degree received, income, insurance status, metropolitan statistical area, and geographic regions), and need factors (self-perceived health status).
Data Analyses
This study compared sociodemographic characteristics across racial and ethnic groups within the study population. The study samples from the earlier study period, 1996-1997, and the latter study periods, 2007-2008, were analyzed separately. Chi-square tests were used for all these comparisons.
This study examined racial and ethnic disparities in 1996-1997 and 2007-2008 and also compared the historical trend of racial and ethnic disparities from 1996-1997 to [2007] [2008] . When examining racial and ethnic disparities in 1996-1997 and 2007-2008, chi-square tests were used initially to compare proportions of individuals eligible for MTM between Whites and the two minority populations, Blacks and Hispanics. In a subsequent multivariate analysis, a logistic regression model was used to control for population sociodemographic and health-related characteristics. Specifically, patient characteristics in the model included predisposing factors (age, gender, and marital status), enabling factors (highest degree received, income, insurance status, metropolitan statistical area, and geographic regions), and need factors (self-perceived health status) according to Andersen's Behavioral Model in Health Services Utilization. 25 In the results, the odds ratios for the dummy variables for Blacks and Hispanics lower than 1 and statistically significant would suggest racial and ethnic disparities in meeting MTM eligibility criteria. All data analyses above took into account the complex survey design of MEPS, including primary sampling units, strata, and personal weights, by using the survey data analysis procedures in SAS 9.2. The statistical significance level was set a priori at 0.05. This study was deemed exempt by the IRB Office at the authors' institution.
RESULTS
Demographic Characteristics
During 1996-1997, within the study sample, there were 5,400 Whites (weighted to 61,276,507), 971 Blacks (weighted to 6, 928, 277) 
MTM Disparities during 1996-1997 among the Medicare Population
This study examined whether higher proportions of Whites met the eligibility criteria than did Blacks and Hispanics among the Medicare population in 1996-1997. Similar proportions of Whites, Blacks, and Hispanics met the eligibility criteria. For example, according to the main analysis for the 2008 eligibility criteria, the proportions meeting the eligibility criteria among Whites, Blacks, and Hispanics were 3.53%, 3.52%, and 3.42%, respectively ( Table 2 ). The differences were not statistically significant between Whites and Blacks nor between Whites and Hispanics (P>0.05). The ranges of the proportions meeting MTM eligibility criteria according to the sensitivity analyses based on 2008 MTM eligibility criteria among Whites, Blacks, and Hispanics were 0.90%-3.80%, 0.70%-3.52%, and 0.90%-3.43%, respectively. The differences between Whites and Blacks were not significant nor were the differences between Whites and Hispanics. Results from multivariate analyses exhibited same pattern. The ranges for the adjusted odds ratios for Blacks to Whites and for Hispanics to Whites were 0.47-0.77 and 0.72-0.98, respectively (P>0.05 for all odds ratios).
The bivariate analysis based on the eligibility criteria in 2010-2011 found that the ranges of the proportions meeting MTM eligibility criteria according to the main and sensitivity analyses among Whites, Blacks, and Hispanics were 5.19%-7.42%, 3.66%-6.24%, and 5.43%-7.01%, respectively. The differences between Whites and Blacks and Whites and Hispanics were not significant. However, according to the multivariate analyses, Blacks were significantly less likely to be eligible for 2010-2011 MTM services than were Whites with odds ratios ranging from 0.50-0.66 (P<0.05); the differences between Whites and Hispanics were not significant according to the multivariate analyses (odds ratios ranged from 0.82-0.92). For example, according to the main analysis for 2010-2011 criteria (Table  3) , the odds ratios for Blacks and Hispanics were 0.50 (P<0.01) and 0.87 (P=0.54), respectively. These odds ratios suggest that Blacks were only 50% as likely to be eligible for MTM services compared to Whites according to the 2010-2011 eligibility criteria.
Bivariate analyses also were conducted on racial and ethnic disparities in exceeding the thresholds for each MTM eligibility criterion among the Medicare population ( Table 4 ). The only statistically significant difference was found in the proportions of exceeding the threshold of number of medications ≥ 2 between Whites and Blacks (P<0.05). The proportions of exceeding all other thresholds for each MTM eligibility criterion were not significant between Whites and Blacks nor between Whites and Hispanics.
MTM Disparities during 2007-2008
Besides the racial and ethnic disparities during the 1996-1997 periods, the patterns of racial and ethnic disparities during the 2007-2008 period were also studied. This study found that Whites generally had a higher likelihood of meeting MTM eligibility criteria than did Blacks and Hispanics based on both 2008 eligibility criteria and 2010-2011 eligibility criteria. According to the main analysis and sensitivity analyses 1-5 for the 2008 criteria, the adjusted odds ratios for Blacks to Whites ranged from 0.71-0.74 (P<0.05 for all odds ratios) and for Hispanics to Whites 0.61-0.70 (P<0.05 for all odds ratios). The adjusted odds ratios for Blacks to Whites and Hispanic to Whites according to sensitivity analyses 6-8 ranges from 0.66-0.76 (P>0.05) and 0.63-0.99 (P>0.05), respectively. According to 2010-2011 criteria, the adjusted odds ratios for Blacks to Whites ranged from 0.64-0.68 (P<0.05 for all odds ratios) and for Hispanics to Whites 0.56-0.61 (P<0.05 for all odds ratios). Because MTM eligibility criteria are based mainly on the utilization of prescription medications, these findings are in keeping with the previous literature that documented lower utilization of prescription medications among Blacks and Hispanics than among Whites. 6, 7, 20, 21 Racial and ethnic disparities in the use of prescription drugs and health services are caused by complicated factors. These factors may include differences across racial and ethnic groups in literacy levels, socioeconomic characteristics, knowledge about disease management, cultural traditions, trust in the health care system, and system and providerlevel problems. 21 Regardless, utilization-based eligibility criteria can lead to disparities in meeting them across racial and ethnic groups.
Historical Trend of Disparities
MTM services are value-based strategies because persons meeting the MTM eligibility criteria have more complicated health issues and medication regimens and are more likely to benefit from MTM services. 26 Because considering value is imperative given current resource challenges, value-based strategies inevitably will be more prevalent in the United States in the future.
The study findings of no significant reduction associated with either 2008 or 2010-2011 MTM eligibility criteria among the Medicare population are consistent with previous government reports of lack of progress on disparity reduction or elimination. For example, the 2010 National Healthcare Quality Report and the National Healthcare Disparities Report mandated by the U.S. Congress emphasized the need to special attention to equitable health care: although health care quality was improving, few disparities in measures for quality of care were getting smaller and almost no disparities in measures for access to care were getting smaller. 3 Specifically, fewer than 20% of disparities in health care quality faced by Blacks, Hispanics, American Indians and Alaska Natives, and the poor exhibited narrowing trend. Additionally, according to the final review of Healthy People 2010, when evaluating changes in overall health disparities by race and ethnicity over time, no change (defined as less than 10 percentage points) in health disparities was found for 111 (69%) of the 169 objectives included in the evaluation. 27 The disparities decreased for only 27 objectives among the 169 objectives included in the evaluation.
The academic community has also documented the lack of progress on disparity reduction or elimination. [4] [5] [6] [7] For example, depression is a major cause of morbidity in late life, and antidepressants have been demonstrated to be effective in reducing depression symptoms among the elderly. However, when Blazer and colleagues studied the association of race to the use of antidepressants between 1986 and 1996 using a stratified probability-based sample of 4,162 senior adults in the Piedmont region of North Carolina, they reported that elderly African-Americans were less likely to take antidepressants than were elderly Whites. They also found that the difference between them increased over the 10 years of the study period. 5 In another study, Blazer and colleagues reported similar findings when examining the time intervals from 1986-1987 to 1989-1990 (interval 1) and from 1992-1993 to 1996-1997 (interval 2). 4 Because minorities are less likely to be eligible for MTM services than are Whites and MTM services can improve patient health outcomes, MTM eligibility criteria may actually aggravate existing racial and ethnic disparities in health outcomes. Additionally, because MTM services can reduce downstream healthcare costs as a result of the improvement of patient health outcomes, while it is a value-based strategy to use MTM eligibility criteria instead of providing MTM services to all patients, disparities associated with MTM services may come with a price tag.
Although it is hard to specify the price tag for disparity implications associated with MTM services without well-thought through research studies, the economic impact of racial and ethnic disparities has been explored particularly in recent years. The study by LaVeist, Gaskin, and Richard estimated that eliminating racial and ethnic disparities would have 28 The state of Colorado estimated the cost of health disparities in Colorado that was born by taxpayers: 29 eliminating disparities could result in cost savings of $80 million annually in diabetes care, $40 million annually in health care related to obesity, and $7.6 million annually in HIV/AIDS care. Waidmann estimated that in 2009, racial and ethnic disparities in diabetes, hypertension, stroke, and renal disease among Blacks, Hispanics, and Whites would cost the health care system $23.9 billion. 30 The extra burden of morbidity and mortality due to disparities may hurt the bottom lines of the business community as well. Specifically, employers need to spend extra health care dollars and incur extra indirect costs because of absenteeism and compromised work productivity (presenteesim). 31 This study has strengths. First, this study makes an important contribution to the literature by exploring the MTM disparity patterns in 1996-1997 and 2007-2008 and examining the historical trend of racial and ethnic disparities in meeting MTM eligibility criteria. This study dispels false hopes that the MTM disparities may be reduced or eliminated over time without any proactive actions from the government. Additionally, by using a federal survey at the national level, the study findings are nationally generalizable. Furthermore, MEPS is a quality database for prescription drug use research thanks to measures taken to improve the accuracy of prescription drug use data by collecting information directly from pharmacies. 22 This study has limitations to consider when interpreting the results. For one, policy scenarios were utilized rather than "real-world" data. An attractive alternative strategy for answering this timely research question is to analyze the actual enrollment in MTM services across racial and ethnic groups. However, information on patient-level enrollment is not currently available at the national level and is not expected to be in the near future. MTM services are paid by Part D plans out of administrative funds, and Part D plans are not required to submit MTM claims to CMS. 12 Additionally, MTM claims databases available through some MTM service companies do not include racial and ethnic information. Even if MTM claims databases contain racial and ethnic characteristics of patients, the MTM service companies and Part D plans are not necessarily willing to share the data because racial and ethnic disparity is a sensitive topic and may bring negative press exposure. However, waiting to answer the important questions of MTM disparities until a perfect data source becomes available would deprive policy makers of timely and valuable information that can assist them to better balance equity and efficiency in policy making. Furthermore, the consistency of this study with previous studies on MTM disparities and historical literature and government reports on the persistency of racial and ethnic disparities testifies to the reliability of the findings from this study. [3] [4] [5] [6] [7] This study included all prescription medications in calculating MTM eligibility, but not just medications covered by health plans. This was a necessary compromise because it is impossible to pinpoint the inclusion of every medication in the diverse formularies of health plans. 12 Nonetheless, because of the repeated documentation of racial and ethnic disparities in the use and costs of prescription medications, it is hard to imagine that a more detailed analysis would produce differential disparity patterns. 6, 7, 20, 21, 32, 33 Additionally, because minorities may be equally or less likely to enroll in Medicare Part D compared to Whites, 34, 35 as far as selection bias is concerned, this study may have underestimated the disparity issues among the minority population than Whites. However, because this study found evidence of disparities, the selection bias issue should not be a major concern. The final study limitation lies in the use of survey data that is prone to issues such as recall error and data entry and processing error. Racial Differences between non-Hispanic Whites and Hispanics were not significant for any criteria. a P<0.05 for the differences between non-Hispanic Whites and non-Hispanic Blacks.
Table 5
Trend of MTM disparities among Medicare population based on 2008 eligibility criteria. Good self-perceived health status 
